Study S000375

Mazdutide Plus Levonorgestrel-Releasing Intrauterine System for Fertility-Sparing Treatment in Overweight or Obese Patients With Atypical Endometrial Hyperplasia or Early Endometrioid Endometrial Cancer

ClinicalTrials.gov record

Registration

Registration: NCT07781150
Acronym: MELIA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 128
Start: 2026-11-01
Primary completion: 2029-06-30
Lead sponsor: Tongji Hospital
Conditions: Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer
Interventions: DRUG:Mazdutide(Dual GLP-1R/GCGR Agonist); DRUG:Placebo; DEVICE:Levonorgestrel-releasing intrauterine system
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Complete response rate of endometrial lesions at 24 week [At 24 weeks after randomization]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.